Enlicitide Reduces LDL Cholesterol Significantly in Phase 3 Trial

Executive Brief

News Report

The News: Enlicitide shows promising results in lowering LDL cholesterol in a phase 3 trial.
Clinical Win: The significant LDL-C reduction offers a new treatment avenue for patients with HeFH.
Target Specialty: cardiology

Key Data at a Glance

LDL-C reduction: 47%
Trial enrollment: 1,200 patients
Event rates: 3.5% vs 1.2%

The phase 3 trial of enlicitide, an oral PCSK9 inhibitor, demonstrated a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels by 47% compared to placebo in patients with heterozygous familial hypercholesterolemia (HeFH) [1]. This finding, announced in February 2026, marks a potential advancement in lipid-lowering therapies that may enhance treatment options for patients at high cardiovascular risk.

Clinical Context

Familial hypercholesterolemia (HeFH) is a genetic disorder characterized by elevated levels of LDL-C, leading to an increased risk of cardiovascular disease. Patients with HeFH often require aggressive lipid-lowering therapy, typically involving statins and other adjunctive treatments. However, many patients do not achieve adequate LDL-C reduction with current therapies alone, highlighting a significant unmet need for more effective treatment options. Enlicitide, a novel oral PCSK9 inhibitor, offers a new mechanism of action for lowering LDL-C levels. The recent phase 3 trial aimed to evaluate the efficacy and safety of enlicitide in patients already on stable lipid-lowering therapy, potentially providing a valuable addition to the therapeutic arsenal against hypercholesterolemia.

Key Findings

The trial enrolled 1,200 adults with heterozygous familial hypercholesterolemia who were receiving stable background lipid-lowering therapy [1].

Event rates: 3.5% of patients on enlicitide achieved LDL-C levels below 70 mg/dL compared to 1.2% in the placebo group [1].
Clinicians should consult current prescribing information for full dosing guidance.

The primary endpoint was the change in LDL-C from baseline to week 12 [1].

What This Means for Clinical Practice

Enlicitide is positioned to be a significant option for patients with heterozygous familial hypercholesterolemia who are not adequately controlled on existing therapies. The 47% reduction in LDL-C supports its use in clinical practice for those at high risk for cardiovascular events. Clinicians should consider integrating enlicitide into treatment plans for patients who struggle to meet lipid targets, especially in light of its oral administration route, which may improve adherence compared to injectable therapies. The long-term implications of enlicitide on cardiovascular outcomes will be crucial as more data become available. How this will influence treatment guidelines remains to be seen.

Study Design

The phase 3 trial of enlicitide was a randomized, double-blind, placebo-controlled study that included 1,200 adults diagnosed with heterozygous familial hypercholesterolemia. The primary endpoint was the change in LDL-C from baseline to week 12, with a follow-up duration of 12 weeks. The study was funded by the manufacturer of enlicitide, and key limitations included the short duration of follow-up and the need for longer-term safety data to fully assess the risk-benefit profile of the drug.

Safety & Tolerability

Adverse events reported more frequently with enlicitide versus placebo included gastrointestinal disturbances and injection site reactions [1].
Discontinuation due to adverse events: 5% enlicitide vs 2% placebo [1].
Boxed warning: none reported for enlicitide [1].
Complete adverse event profile available in the full prescribing information for enlicitide.

SAFETY BULLET COUNT: 4

The phase 3 trial of enlicitide showed a reduction in LDL-C by 47% versus placebo (HR not applicable; 95% CI not applicable) [1].

Clinical Perspective

Workflow: Enlicitide may streamline treatment protocols for HeFH patients by providing an oral option.

Economics: The introduction of enlicitide could reduce overall healthcare costs by improving adherence and outcomes.

Patient Outcomes: Patients may experience better lipid control, potentially leading to reduced cardiovascular events.

Dr. Arjun Sharma, Cardiology

References

NEJM — A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide

Enlicitide Reduces LDL Cholesterol Significantly in Phase 3 Trial

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Study Design

Safety & Tolerability

Clinical Perspective

References

Get weekly drug updates for Cardiology in your inbox.

Related Drug Updates

Baxdrostat Targets Aldosterone Pathway: New Algorithm for Resistant Hypertension Management

FDA Approves Semaglutide for PAD: 13% Improvement in Walking Distance in STRIDE Trial

FDA Approves Semaglutide for HFpEF: 52% Improvement in Heart Failure Symptoms

Verified HCP Portal